HYPERFINE Stock Price, News & Analysis

Hyperfine, Inc. (Nasdaq: HYPR) reported Q1 2022 revenues of $1.509 million, a significant increase from $0.331 million in Q1 2021. The net loss was $23.775 million, or $0.34 per share, compared to a net loss of $7.794 million in the same quarter last year. The company installed 11 commercial systems in Q1 2022, raising the total installed base to 38 commercial systems and 85 total systems. Management projects annual revenues between $10 million and $12 million and expects 50 to 60 units installed by year-end.

Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).

Hyperfine, Inc. (Nasdaq: HYPR) has announced it will release its first quarter 2022 financial results on May 11, 2022. The company, known for creating the world's first FDA-cleared portable MRI system, Swoop®, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Interested investors can listen by calling specified numbers or via a live webcast on Hyperfine's investor page. The Swoop system aims to enhance patient access to medical imaging, enabling rapid diagnoses in various clinical settings.

Hyperfine (Nasdaq: HYPR) reported its fourth quarter and full year 2021 results, highlighting significant achievements and continued expansion. For Q4, revenue rose to $0.436 million from $0.207 million in Q4 2020, while the annual revenue reached $1.496 million compared to $0.294 million. However, the net loss for Q4 was $26.085 million, or $2.73 per share, compared to a net loss of $6.862 million in the prior year. The company projects 2022 revenues between $10 to $12 million and expects to install 50 to 60 commercial units.

Hyperfine, Inc. (Nasdaq: HYPR) will announce its financial results for Q4 and full-year 2021 on March 23, 2022, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. The company developed Swoop®, the first FDA-cleared portable MRI system, aimed at enhancing patient access to diagnostic imaging. Swoop's affordability and ease of use allow rapid diagnoses in various clinical settings, offering high-quality imaging at lower magnetic field strengths.

Hyperfine, creator of the first FDA-cleared portable MRI system, Swoop, announced participation in the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 2:10 PM ET. The presentation will be accessible via a live and archived webcast on their website's Investors section. Swoop enables rapid diagnosis and treatment at point-of-care settings, producing high-quality images with lower magnetic field strength, offering significant benefits in emergency and critical care environments.

Hyperfine, Inc. (Nasdaq:HYPR) announced the deployment of its Swoop portable MRI system at Queen's University and Kingston Health Sciences Centre in Northern Ontario. This move aims to enhance healthcare access for six remote communities, alleviating the need for lengthy medical transfers due to conventional MRI unavailability. The initiative will also support a study on the utility of the portable MRI in remote settings. Hyperfine's recent Health Canada medical device license and commercial launch further validates its innovative approach to imaging technology.

Hyperfine Inc. has appointed Dr. Chip Truwit as the new senior medical director, enhancing its leadership for the growth of its portable MRI technology. Dr. Truwit, a seasoned expert in neuroradiology, previously led diagnostic imaging at Philips Healthcare. His extensive experience, including over 130 published articles and numerous patents, will support Hyperfine’s mission to broaden access to critical MRI imaging. This strategic move aims to improve hospital workflows and enhance care for underserved populations, especially children.

Hyperfine announces the deployment of its FDA-cleared portable MRI, Swoop, at M Health Fairview University of Minnesota Medical Center, marking a significant advancement in neurosurgery technology. This system allows for quick patient scans directly at the bedside, reducing wait times and transportation challenges. Swoop enhances patient safety and diagnostics with AI-driven capabilities, producing high-quality images in minutes. It has previously been deployed at various prestigious medical centers, further establishing its role in improving patient care.